Skip Navigation

Steven P. Treon, MD, PhD


Medical Oncology

Make an Appointment

Physician

  • Director, Bing Center for Waldenström's Macroglobulinemia
  • Senior Physician
  • Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Waldenström’s Macroglobulinemia

Contact Information

  • Office Phone Number617-632-4218
  • Fax617-632-4862

Bio

Dr. Steven Treon is the Director of the Bing Center for Waldenström's Macroglobulinemia Research and an attending physician for medical oncology at Dana-Farber Cancer Institute and Brigham and Women's Hospital, in Boston, Massachusetts. He is also an Associate Professor of Medicine at Harvard Medical School in Boston, and is the Chair of the Waldenström's Macroglobulinemia Clinical Trials Group. After earning a doctorate in tumor immunology from Boston University (BU), Dr. Treon did a postgraduate fellowship in the Department of Microbiology at BU School of Medicine. Dr. Treon received a medical degree from BU School of Medicine and completed an internship in medicine and a residency in internal medicine at BU Medical Center. Dr. Treon also served a clinical fellowship in hematology and oncology at Mass. General Hospital and a research fellowship at Dana-Farber Cancer Institute and Harvard Medical School. He received certification from the American Board of Internal Medicine in 1995, and in medical oncology in 1997. Dr. Treon's main research interests focus on understanding the genetic basis and pathogenesis of Waldenström's macroglobulinemia and the development of therapeutics for this malignancy. He serves on the editorial boards of the Journal of Clinical Oncology, Blood, Clinical Cancer Research, and The Lancet. Dr Treon is a member of several professional societies, including the American Medical Association, American Society of Hematology, American Society of Clinical Oncology, European Society of Hematology and the Massachusetts Medical Society. He has been honored with several research and academic awards from various national and international medical foundations and institutes, including the Robert A. Kyle Award for Waldenström's Macroglobulinemia.

Board Certification:

  • Medical Oncology, 1997

Fellowship:

  • Massachusetts General Hospital, Hematology & Oncology

Residency:

  • Boston University Medical Center, Internal Medicine

Medical School:

  • Boston University School of Medicine

Research

Immunotherapy of Plasma Cell Dyscrasias

Our research has focused on understanding the genetic basis and pathogenesis of Waldenström's macroglobulinemia (WM) and on developing therapeutics for this B cell malignancy, which affects 6,000 to 10,000 patients a year in the United States. As part of our efforts, we recently characterized a familial form of WM, describing its incidence and clinical, laboratory, and cytogenetic characteristics. Importantly, we also demonstrated differing patterns of gene losses among WM patients, including the genes BLIMP1, PAX5, and members of the unfolded protein response (UPR), including XBP1 and IRE1a. Our studies have also provided important insight into the pathogenesis of WM by demonstrating a role for the excess mast cells found in the bone marrow of patients with WM. We recently demonstrated that mast cells serve as potent inducers of growth and enhancers of tumor cell survival through a host of mediators including CD40 ligand, a proliferation-inducing ligand (APRIL), B lymphocyte stimulator (B-LYS) protein, platelet-derived growth factor (PDGF alpha), and vascular endothelial growth factor (VEGF). At the same time, we showed that WM tumor cells induce expression of several of these ligands through soluble CD27. These discoveries have helped in the development of novel therapeutic strategies targeting mast cells and mast cell-tumor cell interactions in WM. In other studies, we have sought to advance the therapy for WM by conducting clinical trials utilizing monoclonal antibodies as single agents and in combination with nucleoside analogs, cytotoxic agents, and immunomodulating agents, as well as phosphodiesterase and proteasome inhibitors. As part of this work, our lab has defined the mechanisms of action and resistance for these agents, specifically the role of Fc gamma receptor polymorphisms in predicting clinical responses to the CD20-directed monoclonal antibody rituximab. This work has resulted in several novel agents for treating WM, and ongoing clinical trials are evaluating their efficacy and toxicity.

Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenström macroglobulinaemia. Br J Haematol. 2021 Mar 13.
View in: PubMed

Reducing treatment toxicity in Waldenström macroglobulinemia. Expert Opin Drug Saf. 2021 Mar 08; 1-8.
View in: PubMed

Clinical application of genomics in Waldenström macroglobulinemia. Leuk Lymphoma. 2021 Feb 11; 1-18.
View in: PubMed

Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition. Epigenomics. 2021 Jan; 13(2):129-144.
View in: PubMed

Management of Waldenström macroglobulinemia in 2020. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):372-379.
View in: PubMed

CXCR4 in Waldenström's Macroglobulinema: chances and challenges. Leukemia. 2021 02; 35(2):333-345.
View in: PubMed

Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib. Br J Haematol. 2021 Feb; 192(3):542-550.
View in: PubMed

A prognostic index predicting survival in transformed Waldenström macroglobulinemia. Haematologica. 2020 Nov 12; Online ahead of print.
View in: PubMed

Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. Lancet Haematol. 2020 Nov; 7(11):e827-e837.
View in: PubMed

The race to stymie BTK: zanu zings. Blood. 2020 10 29; 136(18):1997-1999.
View in: PubMed

Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia. Blood Adv. 2020 10 27; 4(20):5089-5092.
View in: PubMed

Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma. ACS Med Chem Lett. 2020 Nov 12; 11(11):2238-2243.
View in: PubMed

Comparative genomics of CXCR4MUT and CXCR4WT single cells in Waldenström's macroglobulinemia. Blood Adv. 2020 09 22; 4(18):4550-4553.
View in: PubMed

Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. J Clin Oncol. 2021 Feb 20; 39(6):565-575.
View in: PubMed

Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up. Blood Adv. 2020 08 25; 4(16):3952-3959.
View in: PubMed

Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. Hemasphere. 2020 Aug; 4(4):e433.
View in: PubMed

Epigenomics in Waldenström macroglobulinemia. Blood. 2020 07 30; 136(5):527-529.
View in: PubMed

Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials. Hemasphere. 2020 Jun; 4(3):e363.
View in: PubMed

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020 05 21; 135(21):1912-1915.
View in: PubMed

Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia. Br J Haematol. 2020 06; 189(6):1165-1170.
View in: PubMed

Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. J Clin Oncol. 2020 04 10; 38(11):1198-1208.
View in: PubMed

SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. Blood Cancer J. 2020 01 31; 10(1):12.
View in: PubMed

A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia. Leuk Lymphoma. 2020 06; 61(6):1388-1394.
View in: PubMed

CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors. Am J Hematol. 2020 Apr; 95(4):E95-E98.
View in: PubMed

Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas. Blood Adv. 2020 01 14; 4(1):141-153.
View in: PubMed

Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia. Am J Hematol. 2020 Apr; 95(4):372-378.
View in: PubMed

Cutaneous Eruptions from Ibrutinib Resembling EGFR Inhibitor-Induced Dermatologic Adverse Events. J Am Acad Dermatol. 2019 Dec 20.
View in: PubMed

Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells. Blood Adv. 2019 11 12; 3(21):3360-3374.
View in: PubMed

CXCR4S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia. Blood Adv. 2019 10 08; 3(19):2800-2803.
View in: PubMed

What is new in the treatment of Waldenstrom macroglobulinemia? Leukemia. 2019 11; 33(11):2555-2562.
View in: PubMed

How we manage Bing-Neel syndrome. Br J Haematol. 2019 11; 187(3):277-285.
View in: PubMed

Reply to F.D. Leonard. J Clin Oncol. 2019 10 10; 37(29):2701-2702.
View in: PubMed

Correction: Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström Macroglobulinemia. Clin Cancer Res. 2019 Aug 01; 25(15):4860.
View in: PubMed

CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review. Expert Rev Hematol. 2019 10; 12(10):873-881.
View in: PubMed

CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib. Br J Haematol. 2019 11; 187(3):356-363.
View in: PubMed

Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. J Clin Oncol. 2019 06 01; 37(16):1403-1411.
View in: PubMed

Bruton tyrosine kinase degradation as a therapeutic strategy for cancer. Blood. 2019 02 28; 133(9):952-961.
View in: PubMed

Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood. 2019 01 24; 133(4):299-305.
View in: PubMed

Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. Br J Haematol. 2019 02; 184(4):558-569.
View in: PubMed

Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib. Br J Haematol. 2019 05; 185(4):788-790.
View in: PubMed

Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. Blood Adv. 2018 11 13; 2(21):2937-2946.
View in: PubMed

Long survival in patients with Waldenström macroglobulinaemia diagnosed at a young age. Br J Haematol. 2019 05; 185(4):799-802.
View in: PubMed

Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood. 2018 12 13; 132(24):2608-2612.
View in: PubMed

Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia. PLoS One. 2018; 13(10):e0204589.
View in: PubMed

Waldenström Macroglobulinemia: Lessons Learned from Basic and Clinical Research. Hematol Oncol Clin North Am. 2018 10; 32(5):xiii-xiv.
View in: PubMed

Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia. Clin Cancer Res. 2019 01 01; 25(1):369-377.
View in: PubMed

TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia. Br J Haematol. 2019 01; 184(2):242-245.
View in: PubMed

Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res. 2018 12 15; 24(24):6408-6420.
View in: PubMed

Genomic Landscape of Waldenström Macroglobulinemia. Hematol Oncol Clin North Am. 2018 10; 32(5):745-752.
View in: PubMed

Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. J Clin Oncol. 2018 09 20; 36(27):2755-2761.
View in: PubMed

Initial Evaluation of the Patient with Waldenström Macroglobulinemia. Hematol Oncol Clin North Am. 2018 10; 32(5):811-820.
View in: PubMed

The real world of Waldenström's macroglobulinaemia. Lancet Haematol. 2018 07; 5(7):e275-e276.
View in: PubMed

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. N Engl J Med. 2018 Jun 21; 378(25):2399-2410.
View in: PubMed

Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia. Haematologica. 2018 10; 103(10):e466-e468.
View in: PubMed

Spotting the elusive Siberian tiger: Complete response to ibrutinib in a patient with Waldenström Macroglobulinemia. Am J Hematol. 2018 May 14.
View in: PubMed

Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia. JAMA Oncol. 2018 05 01; 4(5):744-745.
View in: PubMed

Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia. Clin Cancer Res. 2018 07 15; 24(14):3247-3252.
View in: PubMed

MYD88 mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4. Haematologica. 2018 09; 103(9):e408-e411.
View in: PubMed

Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia. Br J Haematol. 2019 03; 184(6):1011-1014.
View in: PubMed

BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism. Blood. 2018 05 03; 131(18):2047-2059.
View in: PubMed

Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia. Br J Haematol. 2018 04; 181(1):77-85.
View in: PubMed

Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia. Haematologica. 2018 07; 103(7):e307-e310.
View in: PubMed

Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound. Am J Hematol. 2018 08; 93(4):511-517.
View in: PubMed

Extracellular vesicle-mediated transfer of constitutively active MyD88L265P engages MyD88wt and activates signaling. Blood. 2018 04 12; 131(15):1720-1729.
View in: PubMed

Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia. Am J Hematol. 2018 03; 93(3):E69-E71.
View in: PubMed

Toward personalized treatment in Waldenström macroglobulinemia. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):365-370.
View in: PubMed

What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy. Blood Adv. 2017 Nov 28; 1(25):2486-2490.
View in: PubMed

MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. Br J Haematol. 2018 02; 180(3):374-380.
View in: PubMed

A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader. Cell Chem Biol. 2018 01 18; 25(1):88-99.e6.
View in: PubMed

CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib. Haematologica. 2017 11; 102(11):e452-e455.
View in: PubMed

Comparative outcomes of immunochemotherapy regimens in Waldenström macroglobulinaemia. Br J Haematol. 2017 10; 179(1):106-115.
View in: PubMed

Novel approaches to targeting MYD88 in Waldenström macroglobulinemia. Expert Rev Hematol. 2017 08; 10(8):739-744.
View in: PubMed

The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions. Oncotarget. 2017 May 23; 8(21):35435-35444.
View in: PubMed

Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia. Br J Haematol. 2017 06; 177(5):717-725.
View in: PubMed

Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. Oncoimmunology. 2017; 6(7):e1321184.
View in: PubMed

Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia. Blood. 2017 05 04; 129(18):2519-2525.
View in: PubMed

Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. Br J Haematol. 2017 03; 176(5):728-742.
View in: PubMed

Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia. J Clin Oncol. 2017 Mar 20; 35(9):994-1001.
View in: PubMed

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 02; 15(2):230-269.
View in: PubMed

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017 Feb; 18(2):241-250.
View in: PubMed

Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). Clin Cancer Res. 2017 May 15; 23(10):2400-2404.
View in: PubMed

MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinaemia. Br J Haematol. 2018 02; 180(4):578-581.
View in: PubMed

Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. Haematologica. 2017 01; 102(1):43-51.
View in: PubMed

Epigenomics in Waldenstrom's macroglobulinaemia. Best Pract Res Clin Haematol. 2016 06; 29(2):156-160.
View in: PubMed

Future therapeutic options for patients with Waldenström macroglobulinemia. Best Pract Res Clin Haematol. 2016 06; 29(2):206-215.
View in: PubMed

Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity. Leuk Lymphoma. 2017 04; 58(4):1002-1004.
View in: PubMed

Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis. Oncologist. 2016 Nov; 21(11):1377-1386.
View in: PubMed

Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes. Br J Haematol. 2016 Nov; 175(4):623-630.
View in: PubMed

Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia. Am J Hematol. 2016 10; 91(10):1032-5.
View in: PubMed

Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood. 2016 09 08; 128(10):1321-8.
View in: PubMed

Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome. Br J Haematol. 2017 10; 179(2):339-341.
View in: PubMed

Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. Br J Haematol. 2016 10; 175(1):77-86.
View in: PubMed

Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia. Blood. 2016 08 11; 128(6):827-38.
View in: PubMed

Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. Ther Adv Hematol. 2016 Aug; 7(4):179-86.
View in: PubMed

Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status. Clin Cancer Res. 2016 Dec 15; 22(24):6099-6109.
View in: PubMed

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. 2016 06 23; 127(25):3237-52.
View in: PubMed

Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia. Am J Hematol. 2016 06; 91(6):E312-3.
View in: PubMed

Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia. Br J Haematol. 2017 06; 177(5):808-813.
View in: PubMed

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. J Natl Compr Canc Netw. 2016 04; 14(4):389-400.
View in: PubMed

Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. Leuk Lymphoma. 2016 11; 57(11):2699-701.
View in: PubMed

To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenström Macroglobulinaemia. Br J Haematol. 2017 03; 176(5):822-824.
View in: PubMed

Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia. Blood. 2016 05 26; 127(21):2598-606.
View in: PubMed

Clonal B cells in Waldenström's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling. Leukemia. 2016 05; 30(5):1116-25.
View in: PubMed

miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth. Blood Cancer J. 2016 Jan 15; 6:e380.
View in: PubMed

Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders. Cancer J. 2016 Jan-Feb; 22(1):34-9.
View in: PubMed

Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. Br J Haematol. 2016 Mar; 172(5):709-15.
View in: PubMed

Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. Br J Haematol. 2016 Mar; 172(5):735-44.
View in: PubMed

Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia. Haematologica. 2016 Mar; 101(3):e111-5.
View in: PubMed

Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells. Clin Cancer Res. 2016 05 01; 22(9):2226-36.
View in: PubMed

Rituximab intolerance in patients with Waldenström macroglobulinaemia. Br J Haematol. 2016 08; 174(4):645-8.
View in: PubMed

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2015 Nov; 13(11):1398-435.
View in: PubMed

MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia. N Engl J Med. 2015 Aug 06; 373(6):584-6.
View in: PubMed

Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. Leukemia. 2015 Dec; 29(12):2338-46.
View in: PubMed

Survival outcomes of secondary cancers in patients with Waldenström macroglobulinemia: An analysis of the SEER database. Am J Hematol. 2015 Aug; 90(8):696-701.
View in: PubMed

The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med. 2015 Jun; 21(6):572-80.
View in: PubMed

How I treat Waldenström macroglobulinemia. Blood. 2015 Aug 06; 126(6):721-32.
View in: PubMed

Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia. Am J Hematol. 2015 Jun; 90(6):E122-3.
View in: PubMed

Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015 Apr 09; 372(15):1430-40.
View in: PubMed

Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database. Cancer. 2015 Jul 01; 121(13):2230-6.
View in: PubMed

Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia. Clin Cancer Res. 2015 Jun 01; 21(11):2538-45.
View in: PubMed

The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells. Br J Haematol. 2015 Jul; 170(1):134-8.
View in: PubMed

Biology, prognosis, and therapy of Waldenström Macroglobulinemia. Cancer Treat Res. 2015; 165:177-95.
View in: PubMed

Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol. 2015 Apr; 169(1):81-9.
View in: PubMed

Extramedullary Waldenström macroglobulinemia. Am J Hematol. 2015 Feb; 90(2):100-4.
View in: PubMed

CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells. Br J Haematol. 2015 Mar; 168(5):701-7.
View in: PubMed

Waldenström macroglobulinemia. Hematol Oncol Clin North Am. 2014 Oct; 28(5):945-70.
View in: PubMed

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood. 2014 Aug 28; 124(9):1404-11.
View in: PubMed

Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. Blood. 2014 Jun 19; 123(25):3999-4000.
View in: PubMed

The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia. Leukemia. 2015 Jan; 29(1):169-76.
View in: PubMed

Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. Blood. 2014 Jul 24; 124(4):503-10.
View in: PubMed

Transcriptional repression of plasma cell differentiation is orchestrated by aberrant over-expression of the ETS factor SPIB in Waldenström macroglobulinaemia. Br J Haematol. 2014 Sep; 166(5):677-89.
View in: PubMed

Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. ACS Chem Biol. 2014 May 16; 9(5):1086-91.
View in: PubMed

MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia. Blood. 2014 Apr 24; 123(17):2673-81.
View in: PubMed

miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/ß-catenin/BCL9 pathway. Cancer Res. 2014 Mar 15; 74(6):1801-13.
View in: PubMed

Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. Am J Hematol. 2014 Mar; 89(3):237-42.
View in: PubMed

Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014 May 01; 123(18):2791-6.
View in: PubMed

Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Leukemia. 2014 Aug; 28(8):1698-704.
View in: PubMed

Waldenström macroglobulinemia: from biology to treatment. Expert Rev Hematol. 2014 Feb; 7(1):157-68.
View in: PubMed

The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014 Mar 13; 123(11):1637-46.
View in: PubMed

Proteasome inhibitors in Waldenström macroglobulinemia. Blood. 2013 Nov 07; 122(19):3243-4.
View in: PubMed

Absence of somatic MYD88 L265P mutations in patients with primary Sjogren's syndrome. Genes Immun. 2014 Jan; 15(1):54-6.
View in: PubMed

A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood. 2013 Aug 15; 122(7):1222-32.
View in: PubMed

XIII. Waldenström's macroglobulinaemia: an indolent B-cell lymphoma with distinct molecular and clinical features. Hematol Oncol. 2013 Jun; 31 Suppl 1:76-80.
View in: PubMed

A new era for Waldenstrom macroglobulinemia: MYD88 L265P. Blood. 2013 May 30; 121(22):4434-6.
View in: PubMed

Proceedings of the Seventh International Workshop on Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):181-3.
View in: PubMed

Challenges with serum protein electrophoresis in assessing progression and clinical response in patients with Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):247-9.
View in: PubMed

Comparative response assessment by serum immunoglobulin M M-protein and total serum immunoglobulin M after treatment of patients with Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):250-2.
View in: PubMed

Patients with Waldenström macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administration. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):241-3.
View in: PubMed

microRNA aberrations in Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):205-7.
View in: PubMed

MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013 Mar 14; 121(11):2051-8.
View in: PubMed

Multiple myeloma, version 1.2013. J Natl Compr Canc Netw. 2013 Jan 01; 11(1):11-7.
View in: PubMed

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013 Jan; 160(2):171-6.
View in: PubMed

Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2012 Dec; 12(6):433-7.
View in: PubMed

Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. J Natl Compr Canc Netw. 2012 Oct 01; 10(10):1211-9.
View in: PubMed

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med. 2012 Aug 30; 367(9):826-33.
View in: PubMed

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood. 2012 Aug 30; 120(9):1877-87.
View in: PubMed

Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma. . 2012 Apr; 11(4):942-51.
View in: PubMed

Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: a preliminary study. Cancer Epidemiol. 2012 Jun; 36(3):294-7.
View in: PubMed

Multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1146-83.
View in: PubMed

Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells. Leuk Lymphoma. 2011 Sep; 52(9):1777-86.
View in: PubMed

Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen. Br J Haematol. 2011 Aug; 154(3):357-62.
View in: PubMed

Association of familial disease status with inferior treatment outcome in patients with Waldenstrom's macroglobulinemia. J Clin Oncol. 2011 May 20; 29(15_suppl):8073.
View in: PubMed

Site-specific relative risks of second primary malignancies among patients with Waldenstrom macroglobulinemia. J Clin Oncol. 2011 May 20; 29(15_suppl):e18566.
View in: PubMed

Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. Blood. 2011 Jul 14; 118(2):276-81.
View in: PubMed

Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia. Br J Haematol. 2011 Jul; 154(2):223-8.
View in: PubMed

Matrix metalloproteinase-8 is overexpressed in Waldenström's macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):172-5.
View in: PubMed

Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):133-5.
View in: PubMed

Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):160-3.
View in: PubMed

Report from the Sixth International Workshop on Waldenström's Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):68-73.
View in: PubMed

Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):152-6.
View in: PubMed

Associated malignancies in patients with Waldenström's macroglobulinemia and their kin. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):88-92.
View in: PubMed

Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia. Blood. 2011 Mar 10; 117(10):2918-23.
View in: PubMed

Fc? receptor predictive genomic testing and the treatment of indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2010 Oct; 10(5):321-2.
View in: PubMed

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. Am J Hematol. 2010 Sep; 85(9):670-4.
View in: PubMed

Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010 Jul 01; 115(26):5385-92.
View in: PubMed

Bortezomib as a treatment option in patients with Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2010 Apr; 10(2):110-7.
View in: PubMed

Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10; 28(8):1408-14.
View in: PubMed

Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10; 28(8):1422-8.
View in: PubMed

Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4.
View in: PubMed

IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia. Haematologica. 2010 Mar; 95(3):470-5.
View in: PubMed

How I treat Waldenström macroglobulinemia. Blood. 2009 Sep 17; 114(12):2375-85.
View in: PubMed

Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009 Aug 10; 27(23):3830-5.
View in: PubMed

Clinical and biological significance of microRNA profiling in patients with myeloma. J Clin Oncol. 2009 May 20; 27(15_suppl):8539.
View in: PubMed

TNF-a, retinoid acid and STAT4 pathways are differentially regulated by the HDAC inhibitors, SAHA, TSA and Sirtinol in Waldenstrom's Macroglobulinemia. J Clin Oncol. 2009 May 20; 27(15_suppl):e14582.
View in: PubMed

Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy. Clin Lymphoma Myeloma. 2009 Mar; 9(1):71-3.
View in: PubMed

Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009 Mar; 9(1):100-3.
View in: PubMed

Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009 Mar; 9(1):62-6.
View in: PubMed

Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009 Mar; 9(1):56-8.
View in: PubMed

Advances in the biology and treatment of Waldenström's macroglobulinemia: a report from the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden. Clin Lymphoma Myeloma. 2009 Mar; 9(1):10-5.
View in: PubMed

Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. Br J Haematol. 2009 Apr; 145(1):59-63.
View in: PubMed

International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009 Apr 30; 113(18):4163-70.
View in: PubMed

Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res. 2009 Jan 01; 15(1):355-60.
View in: PubMed

Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009 Jan 10; 27(2):250-5.
View in: PubMed

Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol. 2009 Jan 01; 27(1):120-6.
View in: PubMed

Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood. 2009 Apr 16; 113(16):3673-8.
View in: PubMed

Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. Blood. 2009 Jan 15; 113(3):626-34.
View in: PubMed

Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia. Blood. 2008 Dec 15; 112(13):5111-21.
View in: PubMed

Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias. Biologics. 2008 Sep; 2(3):419-31.
View in: PubMed

Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood. 2008 Dec 01; 112(12):4452-7.
View in: PubMed

The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. Br J Haematol. 2008 Sep; 142(5):775-85.
View in: PubMed

Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2008 Jun; 49(6):1104-7.
View in: PubMed

Phase II trial of the novel oral Akt inhibitor perifosine in relapsed and/or refractory Waldenstrom macroglobulinemia (WM). J Clin Oncol. 2008 May 20; 26(15_suppl):8546.
View in: PubMed

Expression of the deleted in liver cancer-1 gene is regulated by DNA methylation and is a target for therapy in Waldenström's Macroglobulinemia. J Clin Oncol. 2008 May 20; 26(15_suppl):19505.
View in: PubMed

Use of soluble CD27 as a marker of disease burden and the effect of rituximab-induced IgM flare and plasmapheresis in patients with Waldenström's macroglobulinemia. J Clin Oncol. 2008 May 20; 26(15_suppl):8585.
View in: PubMed

Increased prevalence of monoclonal gammopathy, abnormal immunoglobulin levels, and recurrent infections in family members of patients with familial Waldenstrom's macroglobulinemia. J Clin Oncol. 2008 May 20; 26(15_suppl):8540.
View in: PubMed

Serum Immunoglobulin free light chains as markers of disease burden and response to treatment in patients with Waldenstrom's macroglobulinemia. J Clin Oncol. 2008 May 20; 26(15_suppl):8617.
View in: PubMed

Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia. Clin Cancer Res. 2008 Mar 15; 14(6):1849-58.
View in: PubMed

Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood. 2008 May 15; 111(10):5068-77.
View in: PubMed

Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia. Eur J Haematol. 2008 Jun; 80(6):503-9.
View in: PubMed

Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2008 May 01; 111(9):4752-63.
View in: PubMed

Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia. Invest Ophthalmol Vis Sci. 2008 Mar; 49(3):1157-60.
View in: PubMed

CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. Blood. 2008 Dec 01; 112(12):4683-9.
View in: PubMed

Waldenstrom's macrogloblinemia/ lymphoplasmacytic lymphoma. Cancer Treat Res. 2008; 142:211-42.
View in: PubMed

Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol. 2007 Sep; 35(9):1366-75.
View in: PubMed

The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2007 Dec 15; 110(13):4417-26.
View in: PubMed

Novel agents in the treatment of Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2007 Aug; 7 Suppl 5:S199-206.
View in: PubMed

Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res. 2007 Jun 01; 13(11):3320-5.
View in: PubMed

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood. 2007 Oct 01; 110(7):2561-4.
View in: PubMed

Proteomic analysis of waldenstrom macroglobulinemia. Cancer Res. 2007 Apr 15; 67(8):3777-84.
View in: PubMed

Molecular characterization of Waldenstrom's macroglobulinemia reveals frequent occurrence of two B-cell clones having distinct IgH VDJ sequences. Clin Cancer Res. 2007 Apr 01; 13(7):2005-13.
View in: PubMed

Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood. 2007 Jun 01; 109(11):4964-72.
View in: PubMed

Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia. Am J Hematol. 2007 Jan; 82(1):83-4.
View in: PubMed

Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clin Lymphoma Myeloma. 2007 Jan; 7(4):286-90.
View in: PubMed

Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res. 2006 Dec 01; 12(23):7174-9.
View in: PubMed

Hyperviscosity-related retinopathy in waldenstrom macroglobulinemia. Arch Ophthalmol. 2006 Nov; 124(11):1601-6.
View in: PubMed

Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood. 2006 Oct 15; 108(8):2804-10.
View in: PubMed

Phase II study of alemtuzumab in lymphoplasmacytic lymphoma: Results of WMCTG trial 02-079. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7523.
View in: PubMed

Sildenafil citrate suppresses disease progression in patients with Waldenstrom's macroglobulinemia. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7556.
View in: PubMed

Therapeutic targeting of CD70 and CD27-CD70 interactions with the monoclonal antibody SGN-70 in Waldenstrom's Macroglobulinemia (WM). J Clin Oncol. 2006 Jun 20; 24(18_suppl):2509.
View in: PubMed

Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol. 2006 Aug; 17(8):1275-82.
View in: PubMed

Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis. 2006 Jul 01; 43(1):16-24.
View in: PubMed

CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders. Clin Lymphoma Myeloma. 2006 May; 6(6):478-83.
View in: PubMed

Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma. 2006 Mar; 6(5):380-3.
View in: PubMed

Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood. 2006 May 01; 107(9):3442-6.
View in: PubMed

Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol. 2006 Mar; 17(3):488-94.
View in: PubMed

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 2005 Dec 15; 65(24):11712-20.
View in: PubMed

A SCID-hu in vivo model of human Waldenström macroglobulinemia. Blood. 2005 Aug 15; 106(4):1341-5.
View in: PubMed

Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol. 2005 Mar 01; 23(7):1564-77.
View in: PubMed

Report of the Third International Workshop on Waldenstrom's macroglobulinemia. Clin Lymphoma. 2005 Mar; 5(4):215-6.
View in: PubMed

Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenstrom's macroglobulinemia. Clin Lymphoma. 2005 Mar; 5(4):253-6.
View in: PubMed

CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia. Clin Lymphoma. 2005 Mar; 5(4):246-9.
View in: PubMed

CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia. Clin Lymphoma. 2005 Mar; 5(4):273-7.
View in: PubMed

Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. J Clin Oncol. 2005 Jan 20; 23(3):474-81.
View in: PubMed

Extended rituximab therapy in Waldenström's macroglobulinemia. Ann Oncol. 2005 Jan; 16(1):132-8.
View in: PubMed

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005 Jan; 128(2):192-203.
View in: PubMed

Clinical responses to sildenafil in Waldenstrom's macroglobulinemia. Clin Lymphoma. 2004 Dec; 5(3):205-7.
View in: PubMed

Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol. 2004 Oct; 15(10):1481-3.
View in: PubMed

Polymorphisms in Fc?RIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol. 2004 Jul 15; 22(14_suppl):6556.
View in: PubMed

Heterogeneous expression of CD5, CD10, and CD23 in Waldenstrom's macroglobulinemia. J Clin Oncol. 2004 Jul 15; 22(14_suppl):6730.
View in: PubMed

Excess bone marrow mast cells constitutively express CD154 (CD40 ligand) in Waldenstrom's macroglobulinemia and may support tumor cell growth through CD154/CD40 pathway. J Clin Oncol. 2004 Jul 15; 22(14_suppl):6555.
View in: PubMed

Characterization of familial Waldenstrom's Macroglobulinemia. J Clin Oncol. 2004 Jul 15; 22(14_suppl):6558.
View in: PubMed

Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol. 2004 May; 125(3):343-52.
View in: PubMed

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res. 2004 Apr 15; 64(8):2846-52.
View in: PubMed

Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood. Blood. 2004 Oct 01; 104(7):2134-42.
View in: PubMed

Amyloidosis and Waldenström's macroglobulinemia. Hematology Am Soc Hematol Educ Program. 2004; 257-82.
View in: PubMed

Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res. 2003 Oct 15; 63(20):6689-96.
View in: PubMed

Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. Br J Haematol. 2003 May; 121(4):592-6.
View in: PubMed

Defining Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):107-9.
View in: PubMed

Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations. Semin Oncol. 2003 Apr; 30(2):248-52.
View in: PubMed

The malignant clone in Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):132-5.
View in: PubMed

Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):121-6.
View in: PubMed

Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):127-31.
View in: PubMed

Novel biologically based therapies for Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):309-12.
View in: PubMed

Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias. Semin Oncol. 2003 Apr; 30(2):156-60.
View in: PubMed

Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):110-5.
View in: PubMed

Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):116-20.
View in: PubMed

CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood. 2003 Apr 01; 101(7):2762-9.
View in: PubMed

Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002 Oct 29; 99(22):14374-9.
View in: PubMed

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002 Aug 22; 21(37):5673-83.
View in: PubMed

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002 Jun 15; 99(12):4525-30.
View in: PubMed

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002 Jun 01; 99(11):4079-86.
View in: PubMed

Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood. 2002 Mar 15; 99(6):2162-71.
View in: PubMed

CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother. 2002 Jan-Feb; 25(1):72-81.
View in: PubMed

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001 Dec; 15(12):1950-61.
View in: PubMed

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood. 2001 Aug 01; 98(3):795-804.
View in: PubMed

Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias. Expert Opin Investig Drugs. 2001 Aug; 10(8):1521-30.
View in: PubMed

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001 Jul 01; 98(1):210-6.
View in: PubMed

Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies. J Immunother (1991). 2001 May; 24(3):263-271.
View in: PubMed

CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. J Immunother. 2001 May-Jun; 24(3):272-9.
View in: PubMed

Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother. 2001 May-Jun; 24(3):263-71.
View in: PubMed

CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia. J Immunother (1991). 2001 May; 24(3):272-279.
View in: PubMed

Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage. J Immunol. 2000 Dec 01; 165(11):6347-55.
View in: PubMed

The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol. 2000 Dec; 27(6 Suppl 12):79-85.
View in: PubMed

Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood. 2000 Nov 01; 96(9):3147-53.
View in: PubMed

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000 Nov 01; 96(9):2943-50.
View in: PubMed

Immunotherapeutic strategies for the treatment of plasma cell malignancies. Semin Oncol. 2000 Oct; 27(5):598-613.
View in: PubMed

SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem. 2000 Sep 08; 275(36):27845-50.
View in: PubMed

Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis. Amyloid. 2000 Jun; 7(2):126-32.
View in: PubMed

Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6. Clin Cancer Res. 2000 Mar; 6(3):1180-9.
View in: PubMed

Isolation and characterization of human multiple myeloma cell enriched populations. J Immunol Methods. 2000 Feb 21; 235(1-2):11-9.
View in: PubMed

CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. Blood. 2000 Feb 01; 95(3):1039-46.
View in: PubMed

Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens. Ann Oncol. 2000; 11 Suppl 1:107-11.
View in: PubMed

RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells. Oncogene. 1999 Nov 18; 18(48):6733-40.
View in: PubMed

Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy. Semin Oncol. 1999 Oct; 26(5 Suppl 14):97-106.
View in: PubMed

Functional interaction between retinoblastoma protein and stress-activated protein kinase in multiple myeloma cells. Cancer Res. 1999 Mar 15; 59(6):1192-5.
View in: PubMed

Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. Blood. 1999 Mar 01; 93(5):1487-95.
View in: PubMed

Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells. Blood. 1999 Mar 01; 93(5):1482-6.
View in: PubMed

Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood. 1999 Feb 15; 93(4):1287-98.
View in: PubMed

Anti-estrogens induce apoptosis of multiple myeloma cells. Blood. 1998 Sep 01; 92(5):1749-57.
View in: PubMed

The 86-kD subunit of Ku autoantigen mediates homotypic and heterotypic adhesion of multiple myeloma cells. J Clin Invest. 1998 Mar 15; 101(6):1379-88.
View in: PubMed

Interleukin-6 in multiple myeloma and related plasma cell dyscrasias. Curr Opin Hematol. 1998 Jan; 5(1):42-8.
View in: PubMed

p16INK4A promotes differentiation and inhibits apoptosis of JKB acute lymphoblastic leukemia cells. Blood. 1997 Nov 15; 90(10):4106-15.
View in: PubMed

Role of CDK4 and p16INK4A in interleukin-6-mediated growth of multiple myeloma. Leukemia. 1997 Nov; 11(11):1957-63.
View in: PubMed

Characterization of p16(INK4A) expression in multiple myeloma and plasma cell leukemia. Clin Cancer Res. 1997 Nov; 3(11):2173-9.
View in: PubMed

MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Blood. 1997 Sep 01; 90(5):1982-92.
View in: PubMed

IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol. 1997 Sep 01; 159(5):2212-21.
View in: PubMed

Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene. 1997 Aug 14; 15(7):837-43.
View in: PubMed

The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood. 1997 Jul 15; 90(2):754-65.
View in: PubMed

Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells. Blood. 1997 Jul 01; 90(1):279-89.
View in: PubMed

Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells. Clin Cancer Res. 1997 Jun; 3(6):1017-22.
View in: PubMed

Concepts in use of high-dose methotrexate therapy. Clin Chem. 1996 Aug; 42(8 Pt 2):1322-9.
View in: PubMed

CD14 mediated endogenous TNF-alpha release in HL60 AML cells: a potential model for CD14 mediated endogenous cytokine release in the treatment of AML. Leuk Res. 1994 Jan; 18(1):17-21.
View in: PubMed

Lipopolysaccharide (LPS) processing by Kupffer cells releases a modified LPS with increased hepatocyte binding and decreased tumor necrosis factor-alpha stimulatory capacity. . 1993 Feb; 202(2):153-8.
View in: PubMed

Monoclonal antibody therapy in the treatment of Reye's syndrome. Med Hypotheses. 1992 Nov; 39(3):238-42.
View in: PubMed

Beneficial effects of post-transfusional hepatitis in acute myelogenous leukemia may be mediated by lipopolysaccharides, tumor necrosis factor alpha and interferon gamma. Leukemia. 1992 Oct; 6(10):1036-42.
View in: PubMed

Growth restraint and differentiation by LPS/TNF-alpha/IFN-gamma reorganization of the microtubule network in human leukemia cell lines. Leukemia. 1992; 6 Suppl 3:141S-145S.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Mayer 548B
Boston, MA 02215
Get Directions

Ratings

Top